FERRIC CITRATE 210 MG TABLET

What it is

FERRIC CITRATE 210 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ferric citrate.

FDA gives its dosage form as tablet, film coated and its route as oral.

Its labelers, the companies named on the label, are Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Parenteral Iron Replacement and Phosphate Binder.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $188.25 for 30 tablets (30 × $6.27508 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

What NADAC measures · Why 30 tablets · NADAC explanation codes

All 2 NDCs

• 00378-2895-20 · Mylan Pharmaceuticals Inc. · $6.27508 per EA · eff. 2026-09-23 filed
• 00480-2996-97 · Teva Pharmaceuticals, Inc. · $6.27508 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name ferric citrate with FERRIC CITRATE 210 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-02-18, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $6.27508 per EA filed.

Of the 3 other products in FDA’s Parenteral Iron Replacement class priced per EA, 2 have a higher middle NADAC price and 1 a lower one. The one in the middle is AURYXIA 210 MG TABLET, at $7.48095 per EA filed (eff. 2026-02-18).

Of the 34 other products in FDA’s Phosphate Binder class priced per EA, 5 have a higher middle NADAC price and 29 a lower one. The one in the middle is SEVELAMER CARBONATE 800 MG TAB, at $0.214 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-02-18, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.